Tailoring Targeted Therapies for Treatment of BRAF-Mutated Metastatic Colorectal Cancer
BRAF-mutated colorectal cancer is a complex and distinct subset of colorectal cancer, based on its clinical, pathologic, and molecular features as well as initial and second-line therapeutic options. Here is a new and engaging four-part video roundtable from JNCCN–Journal of the National Comprehensive Cancer Network on Tailoring Targeted Therapies for Treatment of BRAF-Mutated Metastatic Colorectal Cancer.
Join moderator Van K. Morris, MD, and his distinguished colleagues Aparna R. Parikh, MD, and Katrina S. Pedersen, MD, MS, as they walk viewers through various clinical considerations in therapeutic decision-making for several different patient scenarios—treatment-refractory, newly diagnosed microsatellite instability–high, and microsatellite-stable. The faculty members briefly review the clinical trial data behind several treatment options—from studies such as BEACON CRC, SWOG S1406, KEYNOTE-177, CheckMate 142, TRIBE, TRIPLETE, FIRE4.5, and BREAKWATER—and how best to assess and select appropriate treatment options for a given patient. In addition, they explore considerations regarding methods of testing for BRAF mutation profiling and the valuable genetic information that can be gleaned from them.
